660 related articles for article (PubMed ID: 27760868)
21. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study.
Zanghì A; Gallo A; Avolio C; Capuano R; Lucchini M; Petracca M; Bonavita S; Lanzillo R; Ferraro D; Curti E; Buccafusca M; Callari G; Barone S; Pontillo G; Abbadessa G; Di Francescantonio V; Signoriello E; Lus G; Sola P; Granella F; Valentino P; Mirabella M; Patti F; D'Amico E
Neurotherapeutics; 2021 Apr; 18(2):1166-1174. PubMed ID: 33844155
[TBL] [Abstract][Full Text] [Related]
22. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of rituximab in refractory RRMS.
Durozard P; Maarouf A; Boutiere C; Ruet A; Brochet B; Vukusic S; Carra-Dalliere C; Labauge P; Mathey G; Debouverie M; Papeix C; Maillart E; Lubetzki C; Bensa C; Gout O; Giannesini C; Stankoff B; Ciron J; Brassat D; Pelletier J; Rico Lamy A; Audoin B
Mult Scler; 2019 May; 25(6):828-836. PubMed ID: 29722639
[TBL] [Abstract][Full Text] [Related]
24. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
[TBL] [Abstract][Full Text] [Related]
25. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
26. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
27. Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.
Kearney H; Miszkiel KA; Yiannakas MC; Altmann DR; Ciccarelli O; Miller DH
Mult Scler; 2016 Jun; 22(7):910-20. PubMed ID: 26432854
[TBL] [Abstract][Full Text] [Related]
28. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Hawker K; O'Connor P; Freedman MS; Calabresi PA; Antel J; Simon J; Hauser S; Waubant E; Vollmer T; Panitch H; Zhang J; Chin P; Smith CH;
Ann Neurol; 2009 Oct; 66(4):460-71. PubMed ID: 19847908
[TBL] [Abstract][Full Text] [Related]
29. Rescue Therapy Using Rituximab for Multiple Sclerosis.
Berenguer-Ruiz L; Sempere AP; Gimenez-Martinez J; Gabaldon-Torres L; Tahoces L; Sanchez-Perez R; Diaz-Marin C
Clin Neuropharmacol; 2016; 39(4):178-81. PubMed ID: 27046661
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.
Hu Y; Nie H; Yu HH; Qin C; Wu LJ; Tang ZP; Tian DS
Autoimmun Rev; 2019 May; 18(5):542-548. PubMed ID: 30844555
[TBL] [Abstract][Full Text] [Related]
31. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
32. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
33. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
Naismith RT; Piccio L; Lyons JA; Lauber J; Tutlam NT; Parks BJ; Trinkaus K; Song SK; Cross AH
Neurology; 2010 Jun; 74(23):1860-7. PubMed ID: 20530322
[TBL] [Abstract][Full Text] [Related]
34. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
[TBL] [Abstract][Full Text] [Related]
35. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
37. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
Houtchens M; Howard D
Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
[TBL] [Abstract][Full Text] [Related]
38. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
39. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
40. Impact of rituximab in Mexican patients with Multiple Sclerosis-A single-center retrospective study.
Bribiesca-Contreras E; García-Estrada C; Gómez-Figueroa E; Zertuche-Ortuño L; Rodríguez-Rivas R; Marcín-Sierra M; Delgado-Niño M; Rivas-Alonso V; Corona-Vázquez T; Flores-Rivera J
Mult Scler Relat Disord; 2022 Feb; 58():103485. PubMed ID: 35042092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
